
Quarterly ResultMay 6, 2026, 04:19 PM
Lyell Immunopharma Q1 Net Loss $24.2M; Cash Runway into Q3 2027
AI Summary
Lyell Immunopharma reported a net loss of $24.2 million for Q1 2026, a significant decrease from $52.2 million in Q1 2025, primarily due to a gain on a securities purchase agreement. The company's cash, cash equivalents, and marketable securities stood at $261.0 million, extending its financial runway into Q3 2027. Key clinical trials for ronde-cel (PiNACLE and PiNACLE-H2H) and LYL273 are progressing, with patient dosing commenced in PiNACLE-H2H and Dose Level 3 for LYL273. The company also closed the second $50 million tranche of its private placement and appointed a new CFO.
Key Highlights
- Q1 2026 net loss was $24.2 million, down from $52.2 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $261.0 million as of March 31, 2026.
- Cash runway is expected to extend into Q3 2027.
- PiNACLE-H2H Phase 3 trial for ronde-cel commenced patient dosing in February 2026.
- LYL273 Phase 1 trial began dosing at Dose Level 3 in March 2026.
- Closed second $50 million tranche of $100 million private placement at $25.61 per share.
- R&D expenses decreased to $36.6 million from $43.4 million YoY.
- Smital Shah appointed Chief Financial and Business Officer in March 2026.
Price Impact
More from LYEL